Re-map the tumour's surface proteins before choosing the next antibody drug
Antibody drugs need their target to still be present. After one fails, checking which surface markers remain would guide the choice of the next one instead of guessing.
Antigen loss and downregulation are documented mechanisms of ADC, bispecific and CAR-T failure. A standardised multiplex panel measuring the main clinical antigens (HER2, TROP2, HER3, CEACAM5, B7-H3, Nectin-4, FOLR1 and others) on a progression biopsy, or by immuno-PET where available, would let clinicians select the next agent by present antigen rather than by tumour type convention.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
- Tumour heterogeneity and clonal evolution · A tumour is many tumours. Treatments that kill most cells leave the rest to grow back, changed.
Pages like this
not linked directly; found by shared links- IdeaAlpha radioligands after ADC failure
Shares Payload-class switching as the rule for ADC sequencing, B7-H3, TROP2, HER2.
- IdeaDual-payload ADCs in first line to prevent resistance
Shares Payload-class switching as the rule for ADC sequencing, TROP2, Acquired resistance to every therapy, HER2.
- IdeaUse SLFN11 status to decide which antibody-drug payload to give next
Shares Payload-class switching as the rule for ADC sequencing, Histopathology & immunohistochemistry, Acquired resistance to every therapy, Antibody-drug conjugate (ADC).
- TermOverexpression
Shares B7-H3, TROP2, HER2, Antibody-drug conjugate (ADC).
- IdeaBlock the survival signals the tumour's neighbours provide
Shares HER3, Single-cell & spatial profiling, Acquired resistance to every therapy.
- IdeaUse the brain's own transport door to carry antibody drugs across
Shares HER3, TROP2, HER2, Antibody-drug conjugate (ADC).
- ProductTusamitamab ravtansine
Shares CEACAM5, Antibody-drug conjugate (ADC).
- IdeaFind the parts of a tumour the drug never reaches
Shares Single-cell & spatial profiling, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy.